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Abstract
Introduction Respiratory viruses are a major cause of
respiratory tract infections. The prevalence of a virus-positive
respiratory sample and its significance in patients requiring
mechanical ventilation remain unknown.
Methods We conducted a cohort study in all consecutive adults
ventilated for more than 48 hours admitted to a 22-bed medical
intensive care unit during a 12-month period. Respiratory
samples at the time of intubation were assessed by culture, by
indirect immunofluorescence assay or by molecular methods in
systematic tracheobronchial aspirates. Patients with a virus-
negative respiratory sample at the time of intubation were
considered unexposed and served as the control group.
Results Forty-five viruses were isolated in 41/187 (22%)
patients. Rhinovirus was the most commonly isolated virus
(42%), followed byherpes simplex virus type 1 (22%) and virus
influenza A (16%). In multivariate analysis controlling for the
Acute Pathophysiology and Chronic Health Evaluation II score,
patients with respiratory disorder at admission (adjusted odds
ratio, 2.1; 95% confidence interval, 0.8–5.1; P = 0.12), with
chronic obstructive pulmonary disease/asthma patients
(adjusted odds ratio, 3.0; 95% confidence interval, 1.3–6.7; P
= 0.01) and with admission between 21 November and 21
March (adjusted odds ratio, 2.8; 95% confidence interval, 1.3–
5.9; P = 0.008) were independently associated with a virus-
positive sample. Among the 122 patients admitted with
respiratory disorder, a tracheobronchial aspirate positive for
respiratory viruses at the time of intubation (adjusted hazard
ratio, 0.273; 95% confidence interval, 0.096–0.777; P < 0.006)
was independently associated with better survival, controlling
for the Simplified Acute Physiology Score II and admission for
cardiogenic shock or cardiac arrest. Among the remaining 65
patients, a virus-positive sample on intubation did not predict
survival.
Conclusion We confirmed the pathogenic role of respiratory
viruses in the intensive care unit, particularly rhinovirus. We
suggest, however, that the prognostic value of virus-associated
respiratory disorder is better than that of other causes of
respiratory disorder.
Introduction
Respiratory viruses represent an important role in the etiology
of community-acquired pneumonia in adults [1-3]. Respiratory
viruses are also the leading cause of acute exacerbations of
chronic obstructive pulmonary disease (COPD)/asthma
patients [4,5], resulting in frequent consultations with a gen-
eral practitioner and hospitalisations. In some cases, invasive
ventilation is required [3,5,6]. The number of studies that doc-
ument the presence of viruses in respiratory samples of criti-
cally ill patients is currently growing in the literature [7-9].
What is really needed, however, are more data on the clinical
significance of these findings, particularly as regards morbidity
and mortality.
COPD = chronic obstructive pulmonary disease; ICU = intensive care unit; IL = interleukin; PCR = polymerase chain reaction; RT = reverse 
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In a previous work we investigated the incidence of nosoco-
mial viral ventilator-associated pneumonia [10]. The aims of
the present study were to determine the epidemiology of and
risk factors for virus-positive respiratory samples taken at the
time of intubation in acutely ill patients, and to compare clinical
outcome (survival and time to ventilated acquired pneumonia)
with and without respiratory viruses, according to the pres-
ence (group 1) or the absence (group 2) of respiratory disor-
der at admission.
Methods
Patients
All consecutively intubated adults admitted to the intensive
care unit (ICU) in the University Hospital of Caen between
September 2003 and September 2004 were screened, as
previously reported [10].
Data collection
Patient characteristics recorded at the time of intubation
included age, sex, main reason for ICU admission, scoring of
disease severity within the first day in the ICU – assessed by
the admission Simplified Acute Physiology Score type II [11],
the Acute Physiology and Chronic Health Evaluation II score
[12] and the admission logistic organ dysfunction system [13]
– and concomitant diseases such as immunocompromised
status defined as HIV infection, neoplasia, innate immunity def-
icit, cystic fibrosis, chronic use of steroids or immunosuppres-
sive drugs. Other comorbidities such as diabetes, COPD/
asthma or cardiovascular diseases were also recorded at
admission.
The main reasons for ICU admission (defined on enrolment
without the knowledge of viral assessment) included cardiac
arrest, septic shock, cardiac shock, mixed shock, hemorrhagic
shock, respiratory distress alone (without other associated
organ failure), acute renal failure, coma, intoxication, surgery
and other. In addition, clinical outcomes assessed by the
occurrence of ventilator-associated pneumonia and death
were recorded.
According to French legislation at the time of the study and
given the observational nature of our study, no ethical commit-
tee approval was requested and thus no informed consent
was obtained from the patients.
Virologic assessment
Details of the virologic methods for virus detection are pub-
lished elsewhere [10]. Briefly, tracheobronchial aspirates per-
formed at the time of intubation were assessed by culture, by
indirect immunofluorescence assay or by molecular methods
(PCR or RT-PCR) using previously described procedures [14-
17].
The following viruses were tested: parainfluenza virus 1,
parainfluenza virus 2, parainfluenza virus 3 and parainfluenza
virus 4, influenza virus A, influenza virus B and influenza virus
C, respiratory syncytial virus, metapneumovirus, rhinovirus,
coronavirus 229E and coronavirus OC43, adenovirus,
cytomegalovirus and herpes simplex virus. Chlamydia pneu-
moniae and Mycoplasma pneumoniae were also detected by
PCR assay.
Respiratory specimens were processed for PCR or RT-PCR at
the end of the study period. One positive sample and several
negative control samples were included for each infectious
agent, which were treated identically to the virus samples
throughout. Results of conventional methods for viral isolation,
routinely performed (in case of respiratory disorder), were
transmitted weekly to the clinicians. Antiviral drugs could be
used during the study period for proven herpes simplex virus
or cytomegalovirus infection in immunocompromised patients.
Definitions
Pneumonia was defined as any acute septic episode with res-
piratory symptoms (cough, sputum production, dyspnea, pleu-
retic chest pain or altered mental status) and a radiographic
infiltrate that was neither preexisting or of other known cause
[18]. Pneumonia occurring after 48 hours of hospitalisation
was considered nosocomial. Ventilator-associated pneumonia
was defined as described elsewhere [10]. Acute exacerbation
of COPD was defined according to the NHLBI/WHO Work-
shop Summary [19]. Respiratory disorder was defined as res-
piratory distress alone or any other reasons for admission with
associated respiratory symptoms.
Statistical analysis
Quantitative data and qualitative data were expressed as the
mean ± standard deviation or as the median (range) and per-
centage (95% confidence interval), respectively. Categorical
variables were compared using the chi-square test or
Fischer's exact test, when appropriate. Quantitative variables
were compared using the Student t test or the Mann-Whitney
nonparametric test, when appropriate. The confidence inter-
vals of percentages were based on normal approximation.
We modeled the probability of a positive virus respiratory sam-
ple using a logistic regression model. Because we hypothe-
sised that the pathogenic role of respiratory viruses in the
respiratory tract may differ when associated with respiratory
symptoms or not, we examined outcome according to the
presence (group 1) or the absence (group 2) of respiratory
disorder at admission. To assess the impact of the virus respi-
ratory sample on time to death and time to ventilated acquired
pneumonia, we constructed Kaplan-Meier curves and Cox
models.
A stepwise selection of variables associated with outcome at
P < 0.1 in the univariate analysis was chosen for multivariate
modeling in both the logistic and the proportional hazards
models. Multivariable modeling is a tradeoff between modelAvailable online http://ccforum.com/content/10/5/R142
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complexity and parcimony. Because of our relatively small
sample size, we selected a level of alpha risk <0.25 to remain
in the multivariable model [20] to avoid partial confusion bias.
The level of significance was set at P < 0.05, and all tests were
two-sided.
We used EPI-INFO version 6.04dfr software (EPI-INFO; CDC,
Atlanta, GA, USA) for data collection, and used EPI-INFO and
SAS version 9.1 software (SAS Institute Inc., Cary, NC, USA)
for data analysis.
Results
Prevalence and baseline characteristics
Among 653 patients admitted to our ICU during the study
period, a tracheobronchial aspirate was taken for viral studies
in 187 patients, as shown in Figure 1. The prevalence of admit-
ted patients with at least one virus-positive respiratory sample
was 41/187 (22%; 95% confidence interval, 16–28) at the
time of intubation. Baseline characteristics of patients with or
without a virus-positive respiratory sample are presented in
Table 1. The main reason for admission was respiratory dis-
tress alone (77/187), including 46 cases of pneumonia, nine
cases of acute COPD/asthma exacerbations, 11 cases of pul-
monary edema, five aspirations, two cases of intraalveolar
bleedings, one case of atelectasia, one pneumothorax, one
pulmonary embolism and one case of myasthenia. Forty-five
out of 187 additional patients had respiratory disorders as
associated symptoms at admission.
Virus finding
Forty-five viruses were isolated from the respiratory specimens
of 41 patients (Table 2). Rhinovirus was the most commonly
isolated virus (19/45), followed by herpes simplex virus type 1
(10/45) and virus influenza A (7/45). Rhinovirus detected in
the lower respiratory tract was associated with clinical signs of
acute COPD exacerbation, of pneumonia or of pulmonary
edema in all cases except in four patients, and virus influenza
was associated with acute respiratory or cardiac failure in all
cases but one. Viral coinfection was detected in four patients:
one case of rhinovirus and virus parainfluenza 3, one case of
rhinovirus and cytomegalovirus, one case of herpes simplex
virus type 1 and virus influenza A, and one case of herpes
Figure 1
Profile of the study Profile of the study. ICU, intensive care unit.Critical Care    Vol 10 No 5    Daubin et al.
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simplex virus type 1 and coronavirus. We reported two sea-
sonal peaks: December for virus influenza A and March for rhi-
novirus (Figure 2). Other viral detection details are presented
in Table 2.
Risk factors associated with a virus-positive sample
In univariate analysis (Table 1), COPD/asthma patients (P =
0.0012), admission between 21 November and 21 March (P
= 0.003) and admission with respiratory disorder (P = 0.03)
were significantly more prevalent in patients with a virus-posi-
tive sample. In addition, patients with a virus-positive sample
had a nonsignificant lower Acute Physiology and Chronic
Health Evaluation II score compared with patients with a virus-
negative sample (18.0 versus 20.9, respectively; P = 0.057).
In multivariate analysis controlling for Acute Physiology and
Chronic Health Evaluation II score and respiratory disorder,
the COPD/asthma patients and admission between 21
November and 21 March remained significantly associated
with a virus-positive sample, as shown in Table 3.
Clinical outcome by virus respiratory sample
The Kaplan-Meier curves of survival according to the presence
of respiratory viruses in group 1 and in group 2 are shown in
Figure 3. A tracheobronchial aspirate positive for respiratory
Figure 2
Viral endemic periods Viral endemic periods. Nb samples, number of samples.
Figure 3
Survival according to viral screening and respiratory disorder at admission Survival according to viral screening and respiratory disorder at admission. Survival according to the result of viral screening on intubation in patients 
with (group 1) and without (group 2) respiratory disorder at admission.Available online http://ccforum.com/content/10/5/R142
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viruses at the time of intubation was independently associated
with better survival in group 1 (P < 0.006) but not in group 2
(P = 0.94), where only a higher Simplified Acute Physiology
Score II (P  < 0.002) and admission for cardiac arrest or
cardiogenic shock (P  = 0.07) predicted time to death, as
shown in Table 4 and Table 5, respectively. A virus-positive
sample did not predict the time to ventilator-associated pneu-
monia in group 1, in group 2 or overall (data not shown).
Discussion
The present study reports that respiratory viruses, as system-
atically screened with sensitive methods at the time of intuba-
tion, are common (22%) among adults ventilated for more than
48 hours, regardless of the reason for admission to the ICU.
Rhinovirus was the most commonly isolated virus. We have
identified, for the first time in this setting, three risks factors
associated with a virus-positive sample – namely, admission
with respiratory disorder, COPD/asthma and admission dur-
ing the winter endemic viral season. These factors highlight
that the diagnosis of respiratory viral infection should be
focused for patients with a respiratory disease, and support
the hypothesis of the clinical impact and pathogenic role of
viral infection. In addition, we suggest that the ICU mortality
might be lower in viral-associated respiratory disorder than in
nonviral-associated respiratory disorder. A virus-positive sam-
ple had no impact on the time to ventilator-associated pneu-
monia, as previously reported in a smaller sample of this cohort
[10].
Our finding differs from previous studies assessing the micro-
b i o l o g i c  p a t t e r n  o f  s e v e r e  p n e u m o n i a  [ 1 8 , 2 1 , 2 2 ]  o r  a c u t e
exacerbation of COPD [7], which reported a lower prevalence
of respiratory tract viral infection, varying from 0% [23] to 16%
[7]. Differences in the diagnosis tests, the lack of a PCR assay
and the limited range of viruses sought may explain this
differential. Our rates of virus-positive respiratory samples
were consistent with the prevalence of respiratory tract viral
infections of 17–48% [8,9,24,25] observed in recent pro-
spective studies using molecular methods for viral detection
and focusing on COPD patients [9,24,25] or patients admit-
ted to the ICU for cardiorespiratory failure [8]. As previously
reported [9,26], the prevalence of virus-positive respiratory
samples was increased in the endemic viral period.
The molecular method used in this study for viral detection is
recognised as the most sensitive technique [27,28]. Nonethe-
Table 1
Baseline characteristics of patients with or without virus-positive respiratory samples at the time of intubation.
Virus-positive samples (n = 41) Virus-negative samples (n = 146) P value
Age (years) 63.2 ± 16.1 62.9 ± 14.5 0.91
Male 31 (75.6) 103 (70.5) 0.53
Comorbidities
Chronic obstructive pulmonary disease/asthma 16 (39.0) 23 (15.7) 0.0012
Cardiologic disease 37 (90.2) 124 (84.9) 0.38
Chronic use of steroids 8 (19.5) 17 (11.6) 0.19
Neoplasia 2 (4.9) 13 (8.9) 0.53
Immunosupressive drugs 2 (4.8) 6 (4.1) 1.0
Neutropenia < 1,000/mm3 0 2 (1.4) 1.0
Community admission 29 (70.7) 98 (67.1) 0.66
Admission between 21 November and 21 March 23 (56.1) 45 (30.8) 0.003
Reason for intensive care unit admission
Respiratory disordera 33 (75.6) 89 (61.0) 0.03
Septic shock 6 (14.6) 21 (14.4) 1.0
Cardiogenic shock or cardiac arrest 2 (4.9) 36 (24.7) 0.004
Comatose 3 (7.3) 24 (16.4) 0.2
Other 3 (7.3) 15 (10.3) 0.78
Acute Physiology and Chronic Health Evaluation type 
II score
18.0 ± 9.3 20.9 ± 8.3 0.057
Simplified Acute Physiology Score II 46.8 ± 18.9 51.5 ± 17.3 0.13
Logistic organ dysfunction system 6.8 ± 3.9 7.8 ± 3.8 0.14
Data are presented as the mean ± standard deviation or number (%), when appropriate. aRespiratory distress alone or associated symptoms with 
another reason for admission.Critical Care    Vol 10 No 5    Daubin et al.
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Table 2
Viruses detected in the respiratory specimens on enrolment.
Patient 
number
COPD/asthma 
patient
Reason for 
admission
Respiratory disorder at 
admission
Virus detected at 
enrolment
Specimen tested by 
molecular methods
Diagnostic method Bacteria detected 
at enrolment
9 Yes Respiratory distress COPD/asthma exacerbation Enterovirus Yes RT-PCR No
14 Yes Coma Aspiration pneumonia Rhinovirus Yes RT-PCR No
16 No Septic shock No Rhinovirus Yes RT-PCR + culture No
21 Yes Respiratory distress COPD/asthma exacerbation Herpes simplex 
virus 1
No Culture No
30 Yes Hemorrhagic shock No Virus influenza A + 
herpes simplex virus
Yes RT-PCR + culture No
31 No Respiratory distress Pulmonary edema Virus influenza A Yes RT-PCR + immuno-
fluorescence
No
37 No Respiratory distress Pneumonia Rhinovirus Yes RT-PCR No
39 No Cardiac arrest Pneumonia Rhinovirus Yes RT-PCR Hemophilus
42 No Respiratory distress Pneumonia Virus influenza A No Immuno-fluorescence Mycoplasma
49 No Respiratory distress Pneumonia Herpes simplex 
virus 1
No Culture Pneumococcus
55 Yes CA Pulmonary edema Virus influenza A No Immuno-fluorescence 
+ culture
No
58 Yes Respiratory distress Pneumonia Virus parainfluenza 
3 + rhinovirus
Yes Immunofluorescence + 
culture
Pneumoccocus + 
moraxella
59 Yes Respiratory distress Pneumonia Virus influenza A Yes RT-PCR + immuno-
fluorescence
No
67 No Respiratory distress Pneumonia Virus influenza A No Immuno-fluorescence No
72 Yes Respiratory distress COPD/asthma exacerbation Respiratory 
syncytial virus
No Immuno-fluorescence No
75 Yes Respiratory distress Pneumonia Virus influenza A Yes RT-PCR + immuno-
fluorescence
No
76 No Coma No Adenovirus No Culture No
78 No Septic shock Pneumonia Rhinovirus Yes RT-PCR Legionella
81 No Septic shock Pneumonia Rhinovirus Yes Culture No
82 Yes Respiratory distress COPD/asthma exacerbation Rhinovirus Yes Culture No
85 Yes Respiratory distress Alveolar bleeding Herpes simplex 
virus 1
Yes Culture No
91 No Respiratory distress Pneumonia Herpes simplex 
virus 1
No Culture MSSA + serratia
94 No Acute hepatitis Pneumonia Rhinovirus Yes RT-PCR Hemophilus
96 No Septic shock Pneumonia Coronavirus + 
herpes simplex virus 
1
Yes RT-PCR + culture Pneumococcus
97 Yes Respiratory distress COPD/asthma exacerbation Rhinovirus Yes RT-PCR No
103 No Respiratory distress Pneumonia Rhinovirus Yes RT-PCR No
105 No Weaning Weaning Rhinovirus Yes RT-PCR No
106 No Coma Pulmonary edema Rhinovirus Yes RT-PCR No
115 Yes Respiratory distress Pneumonia Respiratory 
syncytial virus
No Immuno-fluorescence No
118 No Respiratory distress Pneumonia Rhinovirus Yes Culture Pseudomonas
120 Yes Respiratory distress COPD/asthma exacerbation Enterovirus Yes RT-PCR No
124 No Respiratory distress Pneumonia Herpes simplex 
virus 1
Yes Culture Staphylococcus 
hemolyticus
131 No Septic shock No Rhinovirus Yes RT-PCR NoAvailable online http://ccforum.com/content/10/5/R142
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less, the clinical relevance of a positive respiratory virus PCR
test needs to be appraised. This topic has been discussed in
specific populations that differed from our ventilated ICU
patients; however, no chronic shedding or carriage of respira-
tory virus RNA was found in children [29] and no chronic shed-
ding or carriage of respiratory syncytial virus was found in
COPD patients [30]. Rhinovirus RNA could be detected up to
2–3 weeks after infection [31], without exceeding five weeks
and virus influenza RNA could be detected up to seven days
after infection [32]. These findings suggest that PCR-positive
patients had been infected recently in our study, most of them
within the two weeks before admission.
According to previous studies focusing on patients at high risk
for viral disease [4,6,8,9,24,25,28,33], rhinovirus and virus
influenza were the most frequently recovered viruses. These
epidemiological data underscore the potential pathogenic role
of rhinovirus and of influenza virus as the cause of severe res-
piratory disorder.
In the present study, the proportion of rhinovirus (42%) was
higher than reported in ICU patients [8,9]. While its role as an
important respiratory pathogen remains the subject of debate,
several experimental studies with nasal inoculation demon-
strated that rhinovirus could reach, penetrate and replicate in
the lower airway epithelium and could induce a
proinflammatory response [34,35]. Rhinovirus was also asso-
ciated with severe lower respiratory tract illness [36].
In contrast, influenza virus is recognised to play a major path-
ogenic role during flu outbreaks in the winter-spring season. A
causal relationship between influenza virus infection and hos-
pitalisation for respiratory or cardiac failure has been shown in
vaccine effectiveness studies [37,38].
We failed to demonstrate that patient exposure to respiratory
viruses significantly increased the risk of ventilator-associated
pneumonia. It is commonly reported that respiratory viruses
could facilitate bacterial infection of the airways, by damaging
the respiratory epithelium [39]. Some experimental studies
have reported that respiratory viruses may promote bacterial
adhesion to respiratory epithelial cells, a process that may
increase bacterial colonisation [40,41], and that rhinovirus
may increase the ability of Staphylococcus aureus to internal-
ise into pneumocytes with a mechanism that involves the virus-
induced release of IL-6 and IL-8 and the overexpression of
ICAM-1 [42]. Finally, an epidemiological association has been
described between viral pneumonia and nosocomial infection
[43,44] or respiratory sepsis [26].
136 No Septic shock Pneumonia Herpes simplex 
virus 1
Yes Culture No
139 Yes Respiratory distress COPD/asthma exacerbation Rhinovirus + 
cytomegalovirus
Yes RT-PCR + Culture No
140 No Respiratory distress Pneumonia Rhinovirus Yes RT-PCR + culture No
141 No Respiratory distress Pulmonary edema Rhinovirus Yes RT-PCR No
142 No Respiratory distress Pneumonia Herpes simplex 
virus 1
No Culture Escherichia coli
143 No Respiratory distress Pneumonia Varicella zoster virus Yes RT-PCR No
144 No Respiratory distress Pneumonia Herpes simplex 
virus 1
No Culture Legionella
145 Yes Respiratory distress COPD/asthma exacerbation Rhinovirus Yes RT-PCR + culture No
COPD, chronic obstructive pulmonary disease; MSSA, methicillin-sensitive Staphylococcus aureus.
Table 2 (Continued)
Viruses detected in the respiratory specimens on enrolment.
Table 3
Risk factors for virus-positive respiratory samples at the time of intubation in 187 patients.
Adjusted odds ratio (95% confidence interval)a P value
Chronic obstructive pulmonary disease/asthma 3.0 (1.3–6.7) 0.01
Admission between 21 November and 21 March 2.8 (1.3–5.9) 0.008
Respiratory disorder 2.1 (0.8–5.1) 0.12
Acute Physiology and Chronic Health Evaluation type II score <20 2.0 (0.9–4.3) 0.09
aMultivariate stepwise logistic regression of factors associated with positive respiratory samples. Odds ratio > 1 indicates an increased probability 
of positive respiratory samples. c-index = 0.73Critical Care    Vol 10 No 5    Daubin et al.
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In the subgroup of patients with respiratory disorder, those
with virus-positive samples surprisingly had a better survival.
This result should be interpreted cautiously because it relies
on the control group (that is to say, patients with a virus-nega-
tive sample). This finding does not question the severity of
virus-associated respiratory disorder, but simply suggests that
the prognostic may well differ from other causes of respiratory
disorder. It has been reported that the clinical severity and
inflammatory responses in COPD exacerbations could be
modulated by the nature of the infecting organism [24,25].
We are aware of limitations. The monocenter design of the
study, the relatively small number of included patients,
patients' underlying disease heterogeneity as well as the fact
that 18 patients (8.7%) were eligible but not screened may
limit the interpretation and relevance of our data. Because the
systematic search for bacteria was not obtained at the time of
intubation, 'virus-associated respiratory disorder' does not
necessarily mean virus-induced respiratory disorder. In
addition, the PCR might be too sensitive and we cannot
exclude an asymptomatic carriage of respiratory viruses in the
airways in some cases. In the future, a quantifying viral load
might be another approach to improve the diagnostic
accuracy.
The results reported here may have important implications for
the design and power analysis of a randomised controlled trial
using antiviral drugs. With a 12% mortality rate in the control
group (that is to say, the rate we observed in virus-associated
respiratory disorder), the room for improvement in patients
Table 4
Factors associated with survival in 122 patients with respiratory disorder (reason for admission or associated symptoms at 
admission).
Variable Univariate Cox model Multivariate Cox modela
Hazard ratio (95% confidence interval) P value Adjusted hazard ratio (95% 
confidence interval)
P value
Age 1.022 (0.995–1.050) 0.11
Male 0.630 (0.334–1.187) 0.15
Chronic obstructive pulmonary disease 0.619 (0.095–1.296) 0.20
Acute Physiology and Chronic Health 
Evaluation type II score
1.025 (0.996–1.055) 0.093
Simplified Acute Physiology Score II 1.015 (0.999–1.032) 0.072 1.012 (0.995–1.029) 0.16
Logistic organ dysfunction system 1.020 (0.948–1.098) 0.60
Admission for cardiogenic shock/
cardiac arrest
2.588 (1.146–5.844) 0.022 2.106 (0.924–4.802) 0.08
Virus-positive sample 0. 233 (0.083–0.653) <0.003 0.273 (0.096–0.777) <0.006
aStepwise selection of variables associated with survival with P < 0.10 in the univariate analysis.
Table 5
Factors associated with survival in 65 patients without respiratory disorder.
Variable Univariate Cox model Multivariate Cox modela
Hazard ratio (95% confidence interval) P value Adjusted hazard ratio (95% 
confidence interval)
P value
Age 1.017 (0.986–1.049) 0.29
Male 1.285 (0.496–3.333) 0.61
Chronic obstructive pulmonary 
disease
2.228 (0.738–6.722) 0.16
Acute Physiology and Chronic Health 
Evaluation type II score
1.043 (1.001–1.088) 0.047
Simplified Acute Physiology Score II 1.035 (1.014–1.056) <0.001 1.036 (1.014–1.059) <0.002
Logistic organ dysfunction system 1.147 (1.037–1.269) <0.008
Admission for cardiogenic shock/
cardiac arrest
2.462 (1.035–5.857) 0.042 2.253 (0.938–5.408) 0.07
Virus-positive sample 1.049 (0.306–3.593) 0.94
aStepwise selection of variables associated with survival with P < 0.10 in the univariate analysis.Available online http://ccforum.com/content/10/5/R142
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with viral pneumonia would be lower than that for respiratory
disorder overall (34%). An appropriate sample size would
consequently be necessary to demonstrate the clinical impact,
if any, of antiviral drugs.
Conclusion
We have reported and described the prevalence of virus-pos-
itive respiratory samples taken at the time of intubation in ven-
tilated adults, contributing to improving epidemiological
knowledge in the critical care setting. Using the most sensitive
methods for viral detection, we were able to identify that 22%
of our patients had viruses in their airways. The detection of
respiratory viruses in the respiratory tract, however, was not
always associated with respiratory symptoms, as demon-
strated by the 12% asymptomatic carriage in group 2 (Figure
3, group 2). Finally, we suggest that patients with viruses in the
respiratory tract and respiratory symptoms (suggesting a virus-
associated respiratory disorder) had a better prognosis in the
ICU than patients without viruses and respiratory symptoms
(suggesting other causes of respiratory disorder), as shown in
Figure 3 (group 1). Further studies are necessary: first, to con-
firm the importance of viral infections as a cause of acute res-
piratory failure in patients admitted to the ICU; and, second, to
address the role of antiviral therapy in this population.
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